NanoSight

Press Releases

The Forschungszentrum Dresden-Rossendorf Chooses NanoSight to Characterize Magnetic Nanoparticles

Salisbury, UK, 27th July 2010: The Institute for Radiopharmacy at the Forschungszentrum Dresden-Rossendorf is using NanoSight’s LM-20 nanoparticle characterization system to study magnetic nanoparticles for applications in cancer therapy. 

The research team of Dr Holger Stephan is working to develop magnetic nanoparticles which can be applied in cancer therapy, preferably in combination with intracellular hyperthermia/ablation and endoradionuclide therapies. This requires nanoparticles to be very stable under physiological conditions and they should also avoid accumulation in the reticuloendothelial system.    

Many techniques had been used to characterize the nanoparticles before Dr Stephan discovered the NanoSight system. These included Photon Correlation Spectroscopy (PCS), scanning electron microscopy (SEM) and ultra centrifugation. The NanoSight ability to track individual particles by the scattering of a laser beam has made the study of nanoparticle stability much more convenient.  Nanoparticle Tracking Analysis, NTA, has been used to successfully follow the stability of different systems as a function of temperature in EDTA and different cell media. 

There are three specific goals for measurement: First is to get information about the size distribution of nanoparticles and, more importantly, their stability under physiological relevant conditions, Next is to study the influence of nanoparticle surface modification on the size distribution finally to achieve structure-activity relationships for the nanoparticles on the cellular uptake behaviour (first step) and cancer tissue accumulation (second step), 

Dr Stephan has described several advantages of the NanoSight LM-20 system. He says “the NanoSight provides reliable results on nanoparticles as small as 50nm. Sample handling and measurement is straightforward and experiments are performed more quickly than using PCS. The ability to work directly with relevant solutions removes another block to quickly understanding the behaviour of these magnetic nanoparticles and their ultimate use in treating cancers.” 

“Our goal,” continues Dr Stephan “is to rewrite the medical paradigm, currently being “see and treat” and to make the future one of “detect and prevent.” By working on the combining of different therapeutic methodologies, we will provide synergetic medical effectiveness.” 

To learn more about nanoparticle characterisation using Nanoparticle Tracking Analysis, NTA, please visit www.nanosight.com and register for the latest issue of NanoTrail, the company’s electronic newsletter. 

Dr Holger Stephan of the Forschungszentrum Dresden-Rossendorf with two of his team, Anja Höhle & Madlen Matterna

About NanoSight
NanoSight Ltd, of Amesbury, UK, is the world leading provider of instruments for the optical detection and real time analysis of sub-micron particles. The Company supplies unique instruments for nanoparticle analysis in the sub-micron region that have specific application in virus particle detection and counting. These instruments go far beyond existing light scattering techniques in characterizing polydispersed systems. Founded in 2004, the company currently has approaching 200 systems in service worldwide, having begun commercial sales in 2006.

The Company’s proprietary knowledge and expertise has enabled the delivery of technologies to blue chip companies and universities for direct visualization of individual nanoscale particles in suspension from which independent quantitative estimation of particle size, size distribution and concentration are immediately obtained. The Company has recently launched additions to its advanced Nanoparticle Tracking Analysis (NTA) software that build on the ground-breaking work of NanoSight’s LM20 and LM10 systems.

The Company has a growing base of users worldwide, including BASF, GlaxoSmithKline, 3M Corp, BP, ICI, Roche & Unilever and many universities. For more information, visit NanoSight's website.

For further information
Please contact NanoSight direct or their marketing agency, NetDyaLog Limited: